Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia Vol. 22; no. 4; pp. e259 - e266
• Main Authors: Négrier, C., Abdul Karim, F., Lepatan, L. M., Lienhart, A., López-Fernández, M. F., Mahlangu, J., Pabinger, I., Li, Y., Wolko, D., Voigt, C., Jacobs, I., Santagostino, E.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.07.2016
• Subjects: Adolescent; Adult; albumin fusion proteins; Child; Coagulants - therapeutic use; factor IX; Factor IX - genetics; Factor IX - metabolism; Factor IX - therapeutic use; haemophilia B; Half-Life; Hemophilia B - drug therapy; Hemophilia B - pathology; Hemorrhage - prevention & control; Humans; Middle Aged; orthopaedic surgery; Postoperative Period; Preoperative Care; recombinant fusion proteins; Recombinant Fusion Proteins - biosynthesis; Recombinant Fusion Proteins - pharmacokinetics; Recombinant Fusion Proteins - therapeutic use; Serum Albumin - genetics; Serum Albumin - metabolism; Severity of Illness Index; Surgical Procedures, Operative; Young Adult; factor IX; haemophilia B; orthopaedic surgery; albumin fusion proteins; recombinant fusion proteins

Introduction Recombinant factor IX fusion protein (rIX‐FP) has been developed to improve the pharmacokinetic (PK) profile of factor IX (FIX), allowing maintenance of desired FIX activity between injections at extended intervals, ultimately optimizing haemophilia B treatment. Aim To determine the eff...